阿司匹林与P2Y12反应检测时代的脑室外引流出血并发症
本研究回顾性分析了本中心使用VerifyNow血小板抑制检测期间345例脑室外引流患者的出血并发症。导管相关出血发生率为17.7%,较本中心此前发表的33%显著下降(P < 0.05);但接受与未接受VerifyNow检测的患者间无显著差异,血小板输注未显著降低出血风险。
要点
- 脑室外引流导管相关出血发生率为17.7%,较本中心此前发表的33%显著下降(P < 0.05)。
- 接受与未接受VerifyNow检测的患者间导管相关出血无显著差异。
- 血小板输注未显著降低血小板功能受抑制患者的出血风险。
核心结论
- 本新队列出血发生率低于本中心此前发表的队列,但接受与未接受VerifyNow检测的患者间出血率无显著差异。
- 血小板输注未降低血小板功能受抑制患者的出血发生率。
研究设计与样本
- 回顾性研究,纳入本中心使用VerifyNow血小板抑制检测的2年期间需行脑室外引流的445例患者中的345例,其中208例接受了该检测。
- 脑室外引流指征包括脑血管病并发症(n = 215)、创伤性脑损伤(n = 74)、原发性脑积水(n = 23)和肿瘤(n = 33)。
- 出血定义为CT上导管轨迹旁或紧邻导管轨迹的任何新发高密度区。
主要发现
- 导管相关出血发生于17.7%的患者,与本中心此前发表的检测使用前33%的发生率相比显著下降(P < 0.05)。
- 脑血管病并发症患者的导管相关出血显著下降,检测使用前为39%,本队列为20%(P < 0.01)。
- 接受与未接受VerifyNow检测的患者间导管相关出血无显著下降。
- 血小板输注未显著降低导管相关出血风险。
关键数值与推荐
- 出血定义为CT上导管轨迹旁或紧邻导管轨迹的任何新发高密度区。
- 脑室外引流指征构成:脑血管病并发症n = 215、创伤性脑损伤n = 74、原发性脑积水n = 23、肿瘤n = 33。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Hemorrhagic complications reported from external ventricular drain (EVD) placement range from 10% to 44%. There remains limited literature investigating the incidence, risk factors, and mechanisms to prevent its occurrence, especially in the setting of antiplatelet agent use. We investigated EVD-related hemorrhagic complications after the implementation of VerifyNow platelet inhibition assays at our institution. METHODS: Medical records from 445 patients requiring EVD placement during a 2-year period during which our institution used the assays were reviewed. In total 345 patients were included, and 208 of them underwent assay testing. Indications for EVD included complications of cerebrovascular disease (n = 215), traumatic brain injury (n = 74), primary hydrocephalus (n = 23), and tumor (n = 33). Hemorrhage was defined as any new area of hyperdensity adjacent to or immediately along the catheter trajectory on computed tomography. RESULTS: There was no significant decrease in catheter-induced hemorrhage (CIH) between patients who underwent the VerifyNow assay and those who did not. Platelet transfusion did not significantly decrease the risk of CIH. CIH occurred in 17.7% of patients, significantly decreased when compared with our previously published incidence of 33% before platelet inhibition assay use (P < 0.05). Patients with cerebrovascular disease complications exhibited a significant decrease in CIH, 20% versus 39%, before assay use (P < 0.01). CONCLUSIONS: The incidence of hemorrhage is lower in our new cohort when compared with that of our previously published cohort. Despite the overall decreased rate of hemorrhage, there was no significant difference in hemorrhage rates between patients who did or did not undergo the assay. Platelet transfusion did not decrease the incidence of hemorrhage in patients with inhibited platelet function.
引用
- Majmundar N, Sarris C, Shastri D, et al. Hemorrhagic Complications of External Ventriculostomy in the Aspirin and P2Y12 Response Assay Era. World Neurosurg. 2018. PMID: 30439521. doi:10.1016/j.wneu.2018.10.181
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。